Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | OXER1 | Q8TDS5 | 6/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51354 | 0.79 | DAO (0.38) | ALDH1A1L3MBTL1SIGMAR1HTR1A | |
| SCHEMBL253105 | 0.74 | HTR1A (0.34) | ALDH1A1L3MBTL1SIGMAR1HTR1A | |
| SCHEMBL3941964 | 0.68 | RPS6KA3 (0.43) | PLA2G10 | |
| SCHEMBL3938873 | 0.67 | RPS6KA3 (0.45) | ALDH1A1L3MBTL1PLA2G10 | |
| SCHEMBL2421457 | 0.65 | KDM4E (0.49) | ALDH1A1SIGMAR1HTR1A | |
| SCHEMBL641455 | 0.64 | KMT2A (0.37) | ALDH1A1HTR1A | |
| SCHEMBL8484227 | 0.64 | KEAP1 (0.50) | ALDH1A1HDAC6PPARDPPARA | |
| SCHEMBL3946964 | 0.63 | RPS6KA2 (0.41) | ALDH1A1 | |
| SCHEMBL4177772 | 0.63 | L3MBTL1 (0.42) | ALDH1A1L3MBTL1TERTOXER1 | |
| SCHEMBL27471696 | 0.61 | ALOX5 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183252-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8143243-B2 | 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2396329-A1 | Compounds for the treatment of hepatitis c | Bristol-Myers Squibb Company (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093359-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-2183252-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7652004-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090275561-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090074715-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| WO-2009029384-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074715-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ALDH1A1 163/4885L3MBTL1 4160/4885NR1H2 21/4885 |
| US-20090275561-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ALDH1A1 163/4885L3MBTL1 4160/4885NR1H2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.